Zacks Research Weighs in on Clorox’s Q2 Earnings (NYSE:CLX)

The Clorox Company (NYSE:CLX) – Analysts at Zacks Research dropped their Q2 2025 earnings estimates for Clorox in a report released on Wednesday, November 13th. Zacks Research analyst R. Lohia now anticipates that the company will post earnings of $1.39 per share for the quarter, down from their previous forecast of $1.56. The consensus estimate for Clorox’s current full-year earnings is $6.85 per share. Zacks Research also issued estimates for Clorox’s Q3 2025 earnings at $1.68 EPS, Q4 2025 earnings at $1.92 EPS, FY2025 earnings at $6.85 EPS, Q2 2026 earnings at $1.69 EPS, Q3 2026 earnings at $1.83 EPS, Q4 2026 earnings at $1.90 EPS, FY2026 earnings at $7.17 EPS, Q1 2027 earnings at $1.81 EPS and FY2027 earnings at $7.56 EPS.

A number of other research analysts have also recently issued reports on CLX. Barclays lifted their price target on shares of Clorox from $137.00 to $139.00 and gave the company an “underweight” rating in a research report on Friday, November 1st. Citigroup boosted their price target on Clorox from $165.00 to $170.00 and gave the stock a “neutral” rating in a research report on Friday, September 6th. TD Cowen upgraded Clorox from a “sell” rating to a “hold” rating and upped their price target for the stock from $155.00 to $170.00 in a research note on Wednesday, November 6th. JPMorgan Chase & Co. lifted their price objective on Clorox from $148.00 to $174.00 and gave the company a “neutral” rating in a research note on Friday, October 11th. Finally, Evercore ISI cut their target price on Clorox from $140.00 to $139.00 and set an “underperform” rating on the stock in a research note on Monday, October 14th. Five analysts have rated the stock with a sell rating, ten have issued a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $155.00.

Clorox Stock Performance

Shares of Clorox stock opened at $167.69 on Friday. Clorox has a 12 month low of $127.60 and a 12 month high of $169.09. The firm has a market capitalization of $20.76 billion, a P/E ratio of 58.43, a P/E/G ratio of 3.06 and a beta of 0.41. The company has a current ratio of 1.00, a quick ratio of 0.62 and a debt-to-equity ratio of 11.08. The business has a fifty day simple moving average of $162.39 and a two-hundred day simple moving average of $147.34.

Clorox (NYSE:CLX) last posted its earnings results on Wednesday, October 30th. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.50. Clorox had a return on equity of 316.08% and a net margin of 4.78%. The firm had revenue of $1.76 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter in the prior year, the business earned $0.49 EPS. The business’s revenue for the quarter was up 27.0% on a year-over-year basis.

Clorox Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, November 7th. Shareholders of record on Wednesday, October 23rd were given a $1.22 dividend. The ex-dividend date was Wednesday, October 23rd. This represents a $4.88 annualized dividend and a yield of 2.91%. Clorox’s payout ratio is 170.04%.

Insider Buying and Selling at Clorox

In related news, EVP Angela C. Hilt sold 1,733 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $165.52, for a total value of $286,846.16. Following the transaction, the executive vice president now owns 13,471 shares of the company’s stock, valued at approximately $2,229,719.92. This trade represents a 11.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 0.57% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Mizuho Securities USA LLC increased its position in Clorox by 46,877.8% in the third quarter. Mizuho Securities USA LLC now owns 4,500,000 shares of the company’s stock worth $733,095,000 after buying an additional 4,490,421 shares in the last quarter. Van ECK Associates Corp grew its stake in shares of Clorox by 1,715.5% during the 2nd quarter. Van ECK Associates Corp now owns 1,461,207 shares of the company’s stock valued at $199,411,000 after acquiring an additional 1,380,724 shares during the period. Nuance Investments LLC increased its holdings in Clorox by 150.6% in the 2nd quarter. Nuance Investments LLC now owns 1,597,674 shares of the company’s stock worth $218,035,000 after acquiring an additional 960,094 shares in the last quarter. Ilex Capital Partners UK LLP raised its stake in Clorox by 512.7% during the 3rd quarter. Ilex Capital Partners UK LLP now owns 542,110 shares of the company’s stock worth $88,315,000 after acquiring an additional 453,624 shares during the period. Finally, Wulff Hansen & CO. boosted its position in shares of Clorox by 13,547.0% in the second quarter. Wulff Hansen & CO. now owns 440,116 shares of the company’s stock worth $60,063,000 after purchasing an additional 436,891 shares during the period. 78.53% of the stock is currently owned by institutional investors.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.